3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
594
Stomach Neoplasms
71
Neoplasm Metastasis
56
Neoplasms
35
HER2-positive Breast Cancer
30
Breast Neoplasms, Male
30
Colorectal Neoplasms
28
Brain Neoplasms
23
Carcinoma, Non-Small-Cell Lung
21
Inflammatory Breast Neoplasms
20
Esophageal Neoplasms
20
Pancreatic Neoplasms
13
Triple Negative Breast Neoplasms
12
Lung Neoplasms
11
Endometrial Neoplasms
11
Ovarian Neoplasms
10
Colonic Neoplasms
10
Urinary Bladder Neoplasms
9
Rectal Neoplasms
9
Prostatic Neoplasms
9
Adenocarcinoma
8
Salivary Gland Neoplasms
7
Gallbladder Neoplasms
7
Breast Diseases
7
Biliary Tract Neoplasms
7
Adenocarcinoma Of Esophagus
7
Uterine Cervical Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Sarcoma
6
Pathologic Complete Response
6
Interventions
pertuzumab
1
pazopanib
1
enzalutamide
1
decitabine and cedazuridine drug combination
1
apalutamide
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Risk Assessment
1
Radiotherapy
1
Preoperative Exercise
1
Opdualag
1
Nutritional Support
1
Nivolumab
1
Injections, Subcutaneous
1
Exercise
1
Ethanol
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Adiposity
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Patient Preference
×
Trastuzumab
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts